4.74
-0.25 (-5.01%)
| Previous Close | 4.99 |
| Open | 5.00 |
| Volume | 557,376 |
| Avg. Volume (3M) | 455,825 |
| Market Cap | 279,349,504 |
| Price / Earnings (Forward) | 30.30 |
| Price / Sales | 1.37 |
| Price / Book | 0.550 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 |
| Profit Margin | -21.98% |
| Operating Margin (TTM) | -81.99% |
| Diluted EPS (TTM) | -0.760 |
| Quarterly Revenue Growth (YOY) | 5.40% |
| Total Debt/Equity (MRQ) | 2.30% |
| Current Ratio (MRQ) | 3.92 |
| Operating Cash Flow (TTM) | -56.47 M |
| Levered Free Cash Flow (TTM) | -41.71 M |
| Return on Assets (TTM) | -7.05% |
| Return on Equity (TTM) | -8.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Vanda Pharmaceuticals Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 7.16% |
| % Held by Institutions | 77.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Krensavage Asset Management, Llc | 31 Mar 2025 | 754,381 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (HC Wainwright & Co., 321.94%) | Buy |
| Median | 16.50 (248.10%) | |
| Low | 13.00 (Cantor Fitzgerald, 174.26%) | Buy |
| Average | 16.50 (248.10%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 4.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 14 May 2025 | 13.00 (174.26%) | Buy | 3.92 |
| HC Wainwright & Co. | 07 May 2025 | 20.00 (321.94%) | Buy | 4.38 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 10 Jun 2025 | Announcement | Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S |
| 16 May 2025 | Announcement | Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 |
| 07 May 2025 | Announcement | Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results |
| 05 May 2025 | Announcement | Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 |
| 02 May 2025 | Announcement | Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 |
| 23 Apr 2025 | Announcement | FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |